Refine by
Vaccine Designed Articles & Analysis
25 news found
Creative BioMart, a biotechnology company focused on protein-related research solutions, has recently upgraded its epitope mapping service to better support researchers in therapeutic antibody development, vaccine design, and immunogenicity studies. The updated platform integrates multiple experimental approaches with customizable strategies, enabling more ...
Protheragen focuses on delivering comprehensive vaccine development services, specifically designed to meet the distinct challenges presented by various pathogens. ...
CEPI will provide seed funding of up to US$4.8m to NEC OncoImmunity AS (NOI), a Norway-based subsidiary of NEC, which specializes in artificial intelligence-driven biotechnology, to support the initial development of broadly protective betacoronavirus vaccine candidates. NEC, through NOI, will lead a research consortium including the European Vaccine Initiative ...
CD BioGlyco, a biotechnology company specialized in the field of glycobiology, has developed a series of advanced vaccine development platforms by integrating various advanced technologies to promote the development of glycol-based vaccines. ...
VAX-A1: Vaxcyte continues to advance development of VAX-A1, a novel conjugate vaccine designed to prevent infections caused by Group A Streptococcus (Strep) bacteria, and expects to provide guidance for its anticipated IND application submission to the FDA in the second half of 2022. VAX-PG: Vaxcyte expects to nominate a final vaccine candidate ...
(Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the Jefferies Healthcare Conference in New York City on Thursday, June 9, 2022 at 8:30 a.m. ...
UBS Global Healthcare Conference May 23-25, 2022; New York, NY One-on-one meetings will take place on Tuesday, May 24 and Wednesday, May 25. About Vaxcyte Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel ...
(Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that Company management will participate in a fireside chat at the 21st Annual Needham Virtual Healthcare Conference on Tuesday, April 12, 2022 at 12:45 p.m. ...
Following Prespecified Review of Phase 1 Safety and Tolerability Data, Independent Data Monitoring Committee Recommends Study Proceed as Planned Company Expects to Announce Topline Results from Both the Phase 1 and Phase 2 Portions of the Study Evaluating VAX-24 for the Prevention of Invasive Pneumococcal Disease and Pneumonia by the End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate ...
Company Expects to Announce Topline Results from the Phase 1/2 Study by the End of 2022 Proof-of-Concept Study Will Evaluate the Safety, Tolerability and Immunogenicity of VAX-24 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Designed to Deliver Broad-Spectrum Protection Vaxcyte, Inc. ...
The approach was published in the peer review journal HLA where the first author Anzar and her colleagues also demonstrated how the approach led to the discovery of a new officially named HLA allele, from standard sequencing data routinely used in the design of personalized cancer vaccines. “This approach is an important development in the field of ...
This newly identified pattern may help predict which strains will become variants of concern and inform future vaccine design. “As the COVID-19 pandemic continues to evolve, it is extremely important for our scientific community to begin to understand how a virus like SARS-CoV-2 manages to adapt its genome over time,” said Venky Soundararajan, ...
Vaxcyte, Inc. (Nasdaq: PCVX), a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that it has commenced an underwritten public offering of its common stock and pre-funded warrants. ...
Company Expects to Deliver Topline Immunogenicity Results from the Phase 1/2 Clinical Study by End of 2022 VAX-24 is a 24-Valent Pneumococcal Conjugate Vaccine Candidate Designed to Provide Broad-Spectrum Protection Vaxcyte, Inc. ...
With years of experiences in exosome technology, Creative Biolabs has combined the delivery capabilities of exosomes with targeting technology and biomolecular engineering approaches, and now offers the custom services of exosome targeting to escalate the development of nanoparticles for drug delivery and vaccine design. Creative Biolabs' scientific team is ...
“We have deployed Meissa’s AttenuBlock platform to establish a recombinant live attenuated COVID-19 vaccine that is designed to be genetically stable as well as optimized to drive robust and durable immunity,” said Roderick Tang, Ph.D., Chief Scientific Officer and Cofounder of Meissa Vaccines. ...
Since the discovery of RSV in 1956, no vaccine has been approved for prevention. “We believe that our intranasal live attenuated RSV vaccine candidate, developed on Meissa’s AttenuBlockTM vaccine platform, offers the potential to finally immunize against RSV, which has evaded other vaccine technologies for ...
Researchers arounad the world are putting tremendous effort toward developing vaccines and therapeutic drugs. Creative Biolabs has been dedicated to the discovery and development of different types of vaccines, including in silico vaccine, live attenuated and killed vaccine, recombinant subunit vaccine, and ...
Additional ingredients (known as adjuvants) are added to increase the body’s reaction and strengthen the immune response. However, additional subunit vaccine boosters may be required to maintain ongoing immunity. Some of the newest vaccines for infectious diseases (such as viral vector vaccines and mRNA vaccines) are ...
We anticipate that these new biological insights will help to inform how Evaxion uses its EDEN platform to develop targeted vaccines to combat S. aureus infections.” The paper in Scientific Reports describes how researchers used the novel approach dual RNA sequencing to perform transcriptomic profiling of the infection cycle. ...